{"id":18394,"date":"2021-06-28T08:30:29","date_gmt":"2021-06-28T12:30:29","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18394"},"modified":"2021-06-28T08:30:29","modified_gmt":"2021-06-28T12:30:29","slug":"will-biogens-new-alzheimers-drugs-burden-on-medicare-be-big-huge-or-catastrophic","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18394","title":{"rendered":"Will Biogen\u2019s new Alzheimer\u2019s drug\u2019s burden on Medicare be big, huge, or catastrophic?"},"content":{"rendered":"<p>(By Rachel Cohrs and J. Emory Parker for ST<em>A<\/em>T)<\/p>\n<p>The Food and Drug Administration\u2019s decision to grant wide-ranging approval to the controversial, pricey new Alzheimer\u2019s drug Aduhelm will have an eye-popping impact on Medicare finances. The question is exactly how big the impact will be.\u00a0 Continue reading the article <a href=\"https:\/\/www.statnews.com\/2021\/06\/28\/biogens-alzheimers-drug-medicare-huge-or-catastrophic\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration\u2019s decision to grant wide-ranging approval to<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,21,15],"tags":[],"class_list":["post-18394","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18394"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18394\/revisions"}],"predecessor-version":[{"id":18395,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18394\/revisions\/18395"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}